VirTech Bio
Beverly, US · Founded 2013 · Delaware corporation
Find your way into VirTech Bio
Sign up to see every warm intro you have to VirTech Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the VirTech Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
VirTech Bio develops OxyBridge, a human-derived hemoglobin-based oxygen carrier (HBOC) intended as a blood substitute for time-critical trauma patients in hemorrhagic shock and for pre-transplant donor organ perfusion. The product is aimed at military and civilian trauma care and organ transplantation, using an ultra-polymer design to deliver oxygen and maintain blood pressure without refrigeration.
Founders & leadership

Reported raises · per SEC filings
Form D private placements$500K disclosed across 1 round · 2016
▶$500KraisedJun 2016 · 5 investors · BiotechnologyRule 506(b)
- Joseph TuckerExecutive Officer
- Matias VidalExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $50K
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as VirTech Bio.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseSpecial Operations Command | Phase II | 2018 | $1.8M |
| Department of DefenseSpecial Operations Command | Phase I | 2018 | $148.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $239K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does VirTech Bio do?
- VirTech Bio develops OxyBridge, a human-derived hemoglobin-based oxygen carrier (HBOC) intended as a blood substitute for time-critical trauma patients in hemorrhagic shock and for pre-transplant donor organ perfusion. The product is aimed at military and civilian trauma care and organ transplantation, using an ultra-polymer design to deliver oxygen and maintain blood pressure without refrigeration.
- How much funding has VirTech Bio raised?
- VirTech Bio has disclosed $500K raised across 1 round.
- Where is VirTech Bio headquartered?
- VirTech Bio is headquartered in Beverly, US.



